Business
Natural Alternatives International, Inc. Announces 2021 Q2 and YTD Results
Record Level of Quarterly Sales, Net Income, and Diluted EPS - 2021 Q2: $48.1 million Net Sales (+65.2%), $3.6 million Net Income, $0.57 diluted EPS -
About this update from Natural Alternatives International, Inc.
[{"type":"text","content":"Record Level of Quarterly Sales, Net Income, and Diluted EPS\n - 2021 Q2: $48.1 million Net Sales (+65.2%), $3.6 million Net Income, $0.57 diluted EPS\n - Reaffirms Fiscal Year 2021 Outlook: 30-50% Net Sales Increase\n - Liquidity, Working Capital Position and Sales Backlog Remain Strong\n\n\nCARLSBAD, Calif., Feb. 9, 2021 /PRNewswire/ -- Natural Alternatives International, Inc. (\"NAI\") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $3.6 million, or $0.57 per diluted share, on net sales of $48.1 million for the second quarter of fiscal year 2021 ended December 31, 2020 compared to net income of $0.5 million, or $0.07 per diluted share, in the second quarter of the prior fiscal year. \nNet sales during the three months ended December 31, 2020 increased $19.0 million, or 65.2%, from $29.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased $20.5 million, or 82.5%, from the comparable quarter last year. Private-label contract manufacturing sales increased for a majority of our distribution channels worldwide primarily due to increased shipments of existing products and sales of newly awarded products. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 35.5% to $2.8 million during the second quarter of fiscal 2021, as compared to $4.3 million for the second quarter of fiscal 2020. CarnoSyn® sales have been negatively impacted due to continued competition from generic forms of beta-alanine and the impact the COVID-19 pandemic has had on the sports nutrition industry with limitations on athletic activities, including gyms.\nNet income for the six months ended December 31, 2020 was $5.9 million, or $0.91 per diluted share, compared to net income of $0.6 million, or $0.08 per diluted share, for the six months ended December 31, 2019. \nNet sales during the six months ended December 31, 2020 increased $29.5 million, or 50.6%, from $58.3 million recorded in the comparable prior year period. For the six months ended December 31, 2020, private-label contract manufacturing sales increased $31.5 million, or 62.0%, from the comparable period last year. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 27.1% to $5.4 ...